Immune System Diseases Clinical Trial
Official title:
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Participants wanted for study of mevalonate kinase deficiency (MKD), mevalonic aciduria, or
hyperimmunoglobulinemia with periodic fever syndrome (HIDS).
Patients with MKD (mevalonic aciduria or hyperimmunoglobulinemia with periodic fever syndrome
(HIDS)) may be eligible for a research study conducted at Oregon Health & Science University
(OHSU) in Portland, Oregon USA. The purpose of the study is to find out more about how these
diseases affect body chemistry and health. The researchers also want to find out how
cholesterol in the diet affect blood cholesterol and how the body handles cholesterol. This
is a short-term and long-term dietary study. The long-term goal of this research is to see if
controlling dietary cholesterol can decrease any of the symptoms of the diseases.
The study could involve up to 12 one-week admissions to OHSU over the course of 5 years.
Participants are admitted to the clinical research center for up to a week per visit.
Additional visits at least yearly encouraged. During the week we measure such things as
cholesterol absorption, sterol and bile acid synthesis, mevalonate and mevalonate shunt
products, isoprenoids, fatty acids, leukotrienes, plasma cholesterol and other sterol levels.
Also, the effects of altering dietary cholesterol on plasma 24-S OH-cholesterol, a measure of
brain cholesterol turnover, will be evaluated. Studies of body composition/ metabolism/
growth, development, behavior, sleep, feeding, hearing and vision will be carried out to
document the phenotype and determine if dietary intervention may be helpful.
The objective of the study is to characterize the metabolic and phenotypic consequences of
MKD and study the effects of altering dietary cholesterol in MKD. We hypothesize that some of
the phenotypic effects of MKD are due to altered cholesterol metabolism, but that the
phenotype is predominantly due to derangements in isoprenoid metabolism.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03663933 -
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
|
Phase 2 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT04339777 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
|
Phase 2 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02527187 -
Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
|
Phase 2 | |
Completed |
NCT01441076 -
Anakinra for Behcet s Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01472263 -
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
|
Phase 3 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Suspended |
NCT04642066 -
Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters
|
N/A | |
Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Completed |
NCT04103099 -
Impact of HLNatural Immune Supplement on Colds
|
N/A | |
Recruiting |
NCT03344094 -
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05445284 -
Group Education Trial to Improve Transition for Parents of Adolescents With T1D
|
N/A | |
Recruiting |
NCT06104111 -
Epigenetic Memory of Vitamin D Supplementation
|
Phase 1 | |
Not yet recruiting |
NCT05616117 -
Next-generation Effects of Vitamin D Supplementation in Pregnancy
|
||
Completed |
NCT01510626 -
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
|
Phase 1 | |
Completed |
NCT01490177 -
Single Center Food Allergy Oral Immunotherapy Study
|
Phase 1 | |
Completed |
NCT03922087 -
No-worry Baby Project
|